Quillien 2014 (validation).

Study characteristics
Study design	Cohort
Study setting	Setting: NR Country: France Dates: NR
Selection of participants	Independent validation cohort comprised 50 people with newly diagnosed GBM treated with radiotherapy and concurrent/adjuvant TMZ
Participant characteristics	Sample size: 50 (deaths: NR) Age: median 59; range 41–78 years Sex: % men NR KPS: median NR; KPS 90–100: 22 (44%); KPS 70–80: 23 (46%); KPS < 70: 5 (10%)
Tumour characteristics	GBM: 100% First diagnosis: 100% Biopsy: NR; subtotal resection: NR; total resection: NR IDH1 wild‐type: NR; IDH2 wild‐type: NR
Treatment regimen	Radiotherapy and concurrent/adjuvant TMZ
MGMT promoter methylation tests implemented	PSQ
Dates and follow‐up	Timing of MGMT assessment: NR Start time for follow‐up: NR; follow‐up: median NR; range NR
Notes